Moxifloxacin

Hodgkins Lymphoma

University of CologneSmall moleculePhase 3Dormant

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

141 Active assets in the Hodgkins Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Everolimus OHSU Knight Cancer Institute	Phase 2	BBB
Camustine VIVUS LLC	Phase 2	BBB
Methotrexate Therapeutic Advances in Childhood Leukemia Consortium	Phase 3	BBB
Carboplatin St. Petersburg State Pavlov Medical University	Phase 2	BBB
Cyclosporin A City of Hope Medical Center	Phase 3	BBB

View all 50 →

Same molecule, other indications

Moxifloxacin is also rated in:

bacterial infectious disease with sepsisDormant

BB

Indicative · Phase 3

64 / 100

plasma cell myelomaDormant

B

Indicative · Phase 3

62 / 100

gestational trophoblastic neoplasmDormant

B

Indicative · Phase 3

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.